CCDC9 Inhibitors
CCDC9 inhibitors are a diverse group of compounds that act on various signaling pathways potentially regulating the function of CCDC9. LY294002 and Wortmannin target the PI3K/AKT pathway, a critical regulator of cell survival and proliferation. These inhibitors prevent PI3K-mediated activation of AKT, which in turn could decrease the activity of CCDC9 if it is an AKT-regulated protein. AKT Inhibitor VIII is more selective, specifically targeting AKT and thereby offering a more targeted approach to reducing CCDC9 activity if it is downstream of AKT. Rapamycin's inhibition of mTORC1, a key component downstream of AKT, presents another avenue through which CCDC9 activity might be reduced, by affecting cellular growth and metabolism signals that could involve CCDC9.
Inhibition of other kinases such as GSK-3β by SB 216763 could decrease CCDC9 activity through the accumulation of β-catenin, a potential negative regulator of CCDC9. MEK inhibitors like PD98059 and U0126 block the MAPK/ERK pathway, which could reduce CCDC9 activity if it is under the control of this pathway. Staurosporine, although a broad-spectrum kinase inhibitor, could also decrease CCDC9 activity by inhibiting kinases that activate or modify CCDC9. SP600125's inhibition of the JNK pathway, involved in stress and apoptosis, could influence CCDC9 if it is part of these response pathways.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor that disrupts PI3K/AKT signaling leading to decreased AKT phosphorylation. Since CCDC9 is potentially regulated through AKT-mediated pathways, inhibition of PI3K can result in reduced CCDC9 activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
A covalent inhibitor of PI3K that impairs the PI3K/AKT signaling cascade. This blockade results in diminished AKT activation, which could decrease CCDC9 function if it is AKT-responsive. | ||||||
Akt Inhibitor VIII, Isozyme-Selective, Akti-1/2 | 612847-09-3 | sc-202048 sc-202048A | 1 mg 5 mg | $208.00 $270.00 | 29 | |
A specific allosteric inhibitor of AKT that prevents its phosphorylation and activation. Inhibition of AKT can lead to reduced CCDC9 function if CCDC9 operates downstream of AKT signaling. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor which disrupts mTORC1 signaling, a downstream effect of PI3K/AKT pathway. By inhibiting mTORC1, the compound can indirectly inhibit CCDC9 if it is involved in mTORC1-regulated processes. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
A broad-spectrum kinase inhibitor that can inhibit a variety of kinases, potentially including those that directly phosphorylate CCDC9, leading to its functional inhibition. | ||||||
SB-216763 | 280744-09-4 | sc-200646 sc-200646A | 1 mg 5 mg | $71.00 $202.00 | 18 | |
A GSK-3 beta inhibitor that increases beta-catenin levels. If CCDC9 is negatively regulated by beta-catenin, then inhibiting GSK-3 beta could reduce CCDC9 activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
A MEK inhibitor that prevents the activation of ERK1/2, potentially affecting proteins regulated by the MAPK/ERK pathway. Inhibition of this pathway can lead to reduced CCDC9 activity if it is ERK-dependent. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
A JNK inhibitor that blocks JNK signaling, which is involved in various cellular stress responses. Inhibition of JNK can lead to decreased CCDC9 activity if CCDC9 is part of the JNK response pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
Another MEK inhibitor that suppresses the MAPK/ERK pathway, potentially reducing CCDC9 activity if CCDC9 is regulated by ERK signaling. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A proteasome inhibitor that could prevent the degradation of proteins that regulate CCDC9, leading to an indirect reduction in CCDC9 activity. | ||||||